These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36253453)

  • 21. Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid.
    Ryan MH; Petrone D; Nemeth JF; Barnathan E; Björck L; Jordan RE
    Mol Immunol; 2008 Apr; 45(7):1837-46. PubMed ID: 18157932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A hingeless Fc fusion system for site-specific cleavage by IdeS.
    Novarra S; Grinberg L; Rickert KW; Barnes A; Wilson S; Baca M
    MAbs; 2016; 8(6):1118-25. PubMed ID: 27210548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes.
    Fraldi A; Hemsley K; Crawley A; Lombardi A; Lau A; Sutherland L; Auricchio A; Ballabio A; Hopwood JJ
    Hum Mol Genet; 2007 Nov; 16(22):2693-702. PubMed ID: 17725987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Bacterial Enzyme IdeS Cleaves the IgG-Type of B Cell Receptor (BCR), Abolishes BCR-Mediated Cell Signaling, and Inhibits Memory B Cell Activation.
    Järnum S; Bockermann R; Runström A; Winstedt L; Kjellman C
    J Immunol; 2015 Dec; 195(12):5592-601. PubMed ID: 26553074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS--A Novel Therapeutic Opportunity.
    Winstedt L; Järnum S; Nordahl EA; Olsson A; Runström A; Bockermann R; Karlsson C; Malmström J; Palmgren GS; Malmqvist U; Björck L; Kjellman C
    PLoS One; 2015; 10(7):e0132011. PubMed ID: 26177518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IgG protease Mac/IdeS is not essential for phagocyte resistance or mouse virulence of M1T1 group A Streptococcus.
    Okumura CY; Anderson EL; Döhrmann S; Tran DN; Olson J; von Pawel-Rammingen U; Nizet V
    mBio; 2013 Jul; 4(4):. PubMed ID: 23900173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass.
    Deveuve Q; Lajoie L; Barrault B; Thibault G
    Front Immunol; 2020; 11():168. PubMed ID: 32117299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding.
    Vincents B; von Pawel-Rammingen U; Björck L; Abrahamson M
    Biochemistry; 2004 Dec; 43(49):15540-9. PubMed ID: 15581366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates.
    Murrey DA; Naughton BJ; Duncan FJ; Meadows AS; Ware TA; Campbell KJ; Bremer WG; Walker CM; Goodchild L; Bolon B; La Perle K; Flanigan KM; McBride KL; McCarty DM; Fu H
    Hum Gene Ther Clin Dev; 2014 Jun; 25(2):72-84. PubMed ID: 24720466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The deficient cleavage of M protein-bound IgG by IdeS: insight into the escape of Streptococcus pyogenes from antibody-mediated immunity.
    Su YF; Chuang WJ; Wang SM; Chen WY; Chiang-Ni C; Lin YS; Wu JJ; Liu CC
    Mol Immunol; 2011 Oct; 49(1-2):134-42. PubMed ID: 21925735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correction of murine mucopolysaccharidosis type IIIA central nervous system pathology by intracerebroventricular lentiviral-mediated gene delivery.
    McIntyre C; Derrick-Roberts AL; Byers S; Anson DS
    J Gene Med; 2014; 16(11-12):374-87. PubMed ID: 25418946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid and improved characterization of therapeutic antibodies and antibody related products using IdeS digestion and subunit analysis.
    Sjögren J; Olsson F; Beck A
    Analyst; 2016 May; 141(11):3114-25. PubMed ID: 27156477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients.
    Lorant T; Bengtsson M; Eich T; Eriksson BM; Winstedt L; Järnum S; Stenberg Y; Robertson AK; Mosén K; Björck L; Bäckman L; Larsson E; Wood K; Tufveson G; Kjellman C
    Am J Transplant; 2018 Nov; 18(11):2752-2762. PubMed ID: 29561066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA.
    Rozaklis T; Beard H; Hassiotis S; Garcia AR; Tonini M; Luck A; Pan J; Lamsa JC; Hopwood JJ; Hemsley KM
    Exp Neurol; 2011 Jul; 230(1):123-30. PubMed ID: 21515264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting.
    Velazquez VM; Meadows AS; Pineda RJ; Camboni M; McCarty DM; Fu H
    Mol Ther Methods Clin Dev; 2017 Mar; 4():159-168. PubMed ID: 28345001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The IgG-degrading enzyme of Streptococcus pyogenes causes rapid clearance of anti-glomerular basement membrane antibodies in patients with refractory anti-glomerular basement membrane disease.
    Soveri I; Mölne J; Uhlin F; Nilsson T; Kjellman C; Sonesson E; Segelmark M
    Kidney Int; 2019 Nov; 96(5):1234-1238. PubMed ID: 31563334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enzymatic Inactivation of Endogenous IgG by IdeS Enhances Therapeutic Antibody Efficacy.
    Järnum S; Runström A; Bockermann R; Winstedt L; Crispin M; Kjellman C
    Mol Cancer Ther; 2017 Sep; 16(9):1887-1897. PubMed ID: 28533435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice.
    Bou-Jaoudeh M; Delignat S; Daventure V; Astermark J; Lévesque H; Dimitrov JD; Deligne C; Proulle V; Lacroix-Desmazes S
    Haematologica; 2023 May; 108(5):1322-1334. PubMed ID: 36655430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo enzymatic modulation of IgG antibodies prevents immune complex-dependent skin injury.
    Mihai S; Albert H; Ludwig RJ; Iwata H; Björck L; Collin M; Nimmerjahn F
    Exp Dermatol; 2017 Aug; 26(8):691-696. PubMed ID: 27512946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA Huntaway dog brain.
    King B; Marshall N; Beard H; Hassiotis S; Trim PJ; Snel MF; Rozaklis T; Jolly RD; Hopwood JJ; Hemsley KM
    J Inherit Metab Dis; 2015 Mar; 38(2):341-50. PubMed ID: 25421091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.